Intech Investment Management LLC Acquires Shares of 13,026 Axonics, Inc. (NASDAQ:AXNX)

Intech Investment Management LLC acquired a new stake in Axonics, Inc. (NASDAQ:AXNX) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor acquired 13,026 shares of the company’s stock, valued at approximately $907,000.

Other institutional investors also recently bought and sold shares of the company. AQR Capital Management LLC boosted its stake in shares of Axonics by 0.9% in the second quarter. AQR Capital Management LLC now owns 18,337 shares of the company’s stock worth $1,233,000 after acquiring an additional 161 shares during the last quarter. Xponance Inc. boosted its stake in shares of Axonics by 7.5% in the second quarter. Xponance Inc. now owns 3,231 shares of the company’s stock worth $217,000 after acquiring an additional 225 shares during the last quarter. Arizona State Retirement System boosted its stake in shares of Axonics by 2.5% in the second quarter. Arizona State Retirement System now owns 14,278 shares of the company’s stock worth $960,000 after acquiring an additional 355 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in shares of Axonics by 12.7% in the second quarter. Mercer Global Advisors Inc. ADV now owns 6,981 shares of the company’s stock worth $469,000 after acquiring an additional 785 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Axonics by 4.7% in the second quarter. The Manufacturers Life Insurance Company now owns 21,485 shares of the company’s stock worth $1,444,000 after acquiring an additional 974 shares during the last quarter. 99.48% of the stock is owned by institutional investors and hedge funds.

Axonics Stock Performance

NASDAQ:AXNX opened at $70.98 on Friday. The stock has a 50-day simple moving average of $70.21 and a 200-day simple moving average of $68.79. The stock has a market cap of $3.63 billion, a P/E ratio of -591.45 and a beta of 0.82. Axonics, Inc. has a 1 year low of $55.09 and a 1 year high of $71.05.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a research note on Friday, November 8th. Eight research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $71.00.

Insider Transactions at Axonics

In related news, CFO Kari Leigh Keese sold 2,961 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total value of $205,523.01. Following the completion of the sale, the chief financial officer now directly owns 40,362 shares of the company’s stock, valued at $2,801,526.42. This represents a 6.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.85% of the company’s stock.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.